Australia markets open in 5 hours 20 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
460.11+9.54 (+2.12%)
As of 12:39PM EST. Market open.
Currency in USD

Valuation measures

Market cap (intra-day) 549.29B
Enterprise value 346.05B
Trailing P/E 15.08
Forward P/E 111.58
PEG ratio (5-yr expected) 11.10
Price/sales (ttm)5.93
Price/book (mrq)4.34
Enterprise value/revenue 35.54
Enterprise value/EBITDA 613.04

Trading information

Stock price history

Beta (5Y monthly) 0.16
52-week change 3-3.05%
S&P500 52-week change 323.92%
52-week high 3664.64
52-week low 3418.01
50-day moving average 3499.23
200-day moving average 3539.40

Share statistics

Avg vol (3-month) 31.04M
Avg vol (10-day) 31.27M
Shares outstanding 5104.86M
Float 99.29M
% held by insiders 12.90%
% held by institutions 192.17%
Shares short (11 Feb 2021) 42.11M
Short ratio (11 Feb 2021) 41.96
Short % of float (11 Feb 2021) 42.72%
Short % of shares outstanding (11 Feb 2021) 41.97%
Shares short (prior month 14 Jan 2021) 42.39M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020

Profitability

Profit margin 42.28%
Operating margin (ttm)39.65%

Management effectiveness

Return on assets (ttm)12.88%
Return on equity (ttm)31.77%

Income statement

Revenue (ttm)8.31B
Revenue per share (ttm)77.23
Quarterly revenue growth (yoy)20.00%
Gross profit (ttm)4.46B
EBITDA 3.53B
Net income avi to common (ttm)3.51B
Diluted EPS (ttm)30.52
Quarterly earnings growth (yoy)45.10%

Balance sheet

Total cash (mrq)3.59B
Total cash per share (mrq)34.44
Total debt (mrq)2.71B
Total debt/equity (mrq)24.56
Current ratio (mrq)3.62
Book value per share (mrq)106.05

Cash flow statement

Operating cash flow (ttm)2.62B
Levered free cash flow (ttm)948.45M